Synthesis and receptor binding of IgG1 peptides derived from the IgG Fc region.

J Mol Recognit

Research Group of Peptide Chemistry, Hungarian Academy of Sciences, Eötvös L. University, Budapest 112, PO Box 32, H-1518, Hungary.

Published: October 2004

The IgG binding Fcgamma receptors (FcgammaRs) play a key role in defence against pathogens by linking humoral and cell-mediated immune responses. Impaired expression and/or function of FcgammaR may result in the development of pathological autoimmunity. Considering the functions of FcgammaRs, they are potential target molecules for drug design to aim at developing novel anti-inflammatory and immunomodulatory therapies. Previous data mostly obtained by X-ray analysis of ligand-receptor complexes indicate the profound role of the CH2 domain in binding to various FcgammaRs. Our aim was to localize linear segments, which are able to bind and also to modulate the function of the low affinity FcgammaRs, like FcgammaRIIb and FcgammaRIIIa. To this end a set of overlapping octapeptides was prepared corresponding to the 231-298 sequence of IgG1 CH2 domain and tested for binding to human recombinant soluble FcgammaRIIb. Based on these results, a second group of peptides was synthesized and their binding properties to recombinant soluble FcgammaRIIb, as well as to FcgammaRs expressed on the cell surface, was investigated. Here we report that peptide representing the Arg(255)-Ser(267) sequence of IgG1 is implicated in the binding to FcgammaRIIb. In addition we found that peptides corresponding to the Arg(255)-Ser(267), Lys(288)-Ser(298) or Pro(230)-Val(240) when presented in a multimeric form conjugated to branched chain polypeptide in uniformly oriented copies induced the release of TNFalpha, a pro-inflammatory cytokine from MonoMac monocyte cell line. These findings indicate that these conjugated peptides are able to cluster the activating FcgammaRs, and mediate FcgammaR dependent function. Peptide Arg(255)-Ser(267) can also be considered as a lead for further functional studies.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmr.652DOI Listing

Publication Analysis

Top Keywords

ch2 domain
8
sequence igg1
8
recombinant soluble
8
soluble fcgammariib
8
binding
6
fcgammars
6
synthesis receptor
4
receptor binding
4
binding igg1
4
peptides
4

Similar Publications

Polycyclic tetramate macrolactams (PoTeMs) represent a growing class of bioactive natural products that are derived from a common tetramate polyene precursor, lysobacterene A, produced by an unusual bacterial iterative polyketide synthase (PKS) / non-ribosomal peptide synthetase (NRPS). The structural and functional diversity of PoTeMs is biosynthetically elaborated from lysobacterene A by pathway-specific cyclizing and modifying enzymes. This results in diverse core structure decoration and cyclization patterns.

View Article and Find Full Text PDF

This study investigates the contributions of non-bonding energy (NBE) to the efficacy of four HDAC4 co-crystallized inhibitors (HA3, 9F4, EBE, and TFG) through 100ns Molecular Dynamics (MD) simulations. These inhibitors contain hydroxamic acid (HA3, 9F4, EBE) or diol (TFG) as zinc-binding groups. In PDBs 2VQJ and 2VQM, the HDAC4 catalytic domain is in the 'open' conformation, while in PDBs 4CBT and 6FYZ, the same is in the 'closed' conformation.

View Article and Find Full Text PDF

Comparison of C-type Nanoantibody Produced in Different Expression Systems Implying Potential Clinical Applications.

Mol Pharm

January 2025

Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei 430207, China.

Article Synopsis
  • In the pharmaceutical industry, Chinese hamster ovary cells are commonly used to produce traditional monoclonal antibodies, while nanobodies like C-type nanoantibodies (C-Nabs) are emerging as promising next-generation drugs.
  • The study evaluated various expression systems (bacteria, yeast, mammalian cells) for producing C-Nabs, assessing their binding, stability, and resistance to degradation.
  • Results indicated that yeast is the most effective host for producing C-Nabs, which showed better pharmacokinetic properties when tested in mice, supporting their potential as therapeutic candidates.
View Article and Find Full Text PDF

Human immunoglobulin G (IgG) antibodies are one of the most important classes of biotherapeutic agents and undergo glycosylation at the conserved N297 site in the C2 domain, which is critical for IgG Fc effector functions and anti-inflammatory activity. Hence, technologies for producing authentically glycosylated IgGs are in high demand. While attempts to engineer for this purpose have been described, they have met limited success due in part to the lack of available oligosaccharyltransferase (OST) enzymes that can install linked glycans within the QYNST sequon of the IgG C2 domain.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers analyzed donkey milk IgG using RP-UHPLC-MS/MS to examine its specific glycosylation patterns, revealing the presence of multiple subtypes.
  • Proteomic analysis showed that various IgG subtypes (IgG1, IgG2, IgG3, IgG5, IgG6, and IgG7) had unique glycopeptides linked to a conserved glycosylation site in their heavy-chain regions.
  • Notably, IgG5 exhibited a distinct glycosylation pattern with sialylated glycans, while structural diversity was primarily seen in IgG1, IgG5, and IgG7, highlighting the potential functional properties of donkey milk.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!